ORIGINAL ARTICLES: Translational researchA small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosisRomaine, Sam T.a; Wells-Jordan, Peterb; de Haro, Traceyb; Dave-Thakrar, Avnib; North, Joannab; Pringle, James H.a; Saldanha, GeraldaAuthor Information aDepartment of Cancer Studies, University of Leicester bEMPATH Department of Cellular Pathology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK Correspondence to Gerald Saldanha, MBChB, PhD, Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Level 3 Robert Kilpatrick Clinical Sciences Building, Leicester LE2 7LX, UK Tel :+44 116 252 3228; fax +44 116 252 3274; email: [email protected] Melanoma Research: December 2016 - Volume 26 - Issue 6 - p 580-587 doi: 10.1097/CMR.0000000000000293 Buy Metrics Abstract Melanoma is an aggressive cancer. Outcomes can vary significantly for lesions within the same pathological stage – a problem of increasing relevance with the promise of adjuvant treatments on the basis of immune checkpoint modulators and targeted therapies. The use of a panel of prognostic molecular biomarkers as an adjunct to stage represents a possible solution. Immunohistochemistry-based biomarkers offer greater potential for translation into clinical practice than biomarkers utilizing more complex methods. Many immunohistochemistry-based biomarkers have been identified through discovery studies, but rigorous validation of these is scarce. We take the first steps towards validating a combination of three such biomarkers in a prognostic panel – 5hmC, ki-67 and p16. Immunohistochemistry was performed on a cohort of 50 melanomas to determine the expression of 5hmC, ki-67 and p16. 5hmC and p16 showed statistically significant differences in metastasis-free survival between low-score and high-score groups, whereas the use of all three biomarkers together with stage could predict the 5-year metastasis risk more accurately than stage alone. Our results suggest that the use of multimarker panels to improve the accuracy of prognostic predictions is feasible and worthy of further study. We have shown that a small immunohistochemistry-based panel utilizing simple, inexpensive, reproducible methods can be an effective adjunct to stage in prognostic prediction. A follow-up study consisting of a large cohort of melanomas is now indicated to continue the development of the prognostic panel. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.